IP Library Granted Patent US 8,716,257
Granted Patent B2
US 8,716,257 · App. 13/447,249 · Granted May 6, 2014

CMV gene products promote cancer stem cell growth

Inventors: Charles Cobbs (San Francisco, CA); Liliana Soroceanu (San Francisco, CA)
Assignee: Sutter West Bay Hospitals
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,716,257
App. No.
13/447,249
Granted
May 6, 2014
Kind
B2
Abstract

The disclosure relates generally to compositions and methods useful for inhibiting the infection and propagation of viral particles, particularly members of the Herpesviridae family, and more particularly to cytomegalovirus (CMV) and methods of treating diseases and disorders, including cell proliferative disorders, associated with CMV infection.

Claims (8)

1. A method of inhibiting the proliferation, growth and/or migration of a glioblastoma cell infected with cytomegalovirus in a subject comprising administering to the cell an inhibitor of a cytomegalovirus IE1 gene, comprising a duplex of inhibitory nucleic acids comprising SEQ ID NOS: 6 and 7, wherein the duplex of inhibitory nucleic acids inhibits the expression of the IE1 polypeptide encoded by the IE1 gene.

2. The method of claim 1 further comprising administering to the cell an inhibitor of cytomegalovirus US28 and/or an inhibitor of cytomegalovirus pp71, wherein the inhibitors of US28 and pp71 are inhibitory nucleic acids.

3. The method of claim 2 wherein the inhibitors of US28 and pp71 are siRNA or ribozyme molecules.

4. A method of treating a cell proliferative disease or disorder comprising exposing a cell infected with CMV and having aberrant cell proliferation to at least one siRNA that targets RNA encoded by a CMV IE1 gene, wherein the at least one siRNA is a double stranded RNA (dsRNA) molecule comprising a 3′dTdT and a 5′ phosphate group, under conditions that permit induction of ribonucleic acid interference (RNAi), such that cell proliferation, growth and/or migration of the cell infected with CMV is inhibited and wherein the at least one siRNA comprises SEQ ID NOS:4 and 5, or SEQ ID NOS:6 and 7, or SEQ ID NOS: 4, 5, 6, and 7.

5. The method of claim 4 , wherein the at least one siRNA comprises at least two siRNAs, each targeted to an RNA encoded by a different target gene.

6. The method of claim 4 , wherein the at least one siRNA comprises three different siRNAs, each targeted to an RNA encoded by a different target gene.

7. The method of claim 5 or 6 , wherein the target genes include one or both of cytomegalovirus US28 and pp71.

8. The method of claim 4 , wherein the at least one siRNA is a double stranded RNA (dsRNA) molecule, each strand of which is about 18-29 nucleotides long.

Assignments (2)
CHANGE OF NAME Recorded Apr 27, 2016
From: SUTTER WEST BAY HOSPITALS
To: SUTTER BAY HOSPITALS
Reel/Frame 038542/0160 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2014
From: COBBS, CHARLES; SOROCEANU, LILIANA
To: SUTTER WEST BAY HOSPITALS
Reel/Frame 032240/0092 →
Continuity (2)
Provisional Application 61476234 · Apr 15, 2011
Related Publication 20120264675A1 · Oct 18, 2012